Abstract
In late September 2017, the California Institute for Regenerative Medicine (CIRM) appointed Dr. Maria Millan as its new president and CEO. Millan assumes the mantle of leadership at a fraught moment for CIRM. Of the $3 billion in state bond funds used to establish the agency in 2004, about $335 million will remain by the end of the year to support research and clinical development. What’s left will be largely spent by 2020. If CIRM supporters are unable to secure more funding before then, a number of therapies in the agency’s development pipeline might wither on the vine.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
